A Phase 2 Study of BGJ398 in Patients With Recurrent GBM

Inclusion criteria: 1. Patients with histologically confirmed GBM and/or other glioma subtypes at the time of diagnosis or prior relapse. 2. Written documentation of local or central laboratory determination of amplification or translocation to FGFR1-TACC1, FGFR3-TACC-3 fusion and/or activating mutation in FGFR1, FGFR2,or FGFR3 3. RANO defined tumor progression by MRI in comparison to a prior scan 4. Patients must have received prior external beam radiotherapy and temozolomide. Exclusion criteria: 1. History of another primary malignancy 2. Prior or current treatment with a FGFR inhibitor 3. Neurological symptoms related to underlying disease requiring increasing doses of corticosteroids 4. Patients must not be taking Enzyme Inducing Anti-Epileptic Drug (EIAED). If previously on an EIAED, the patient must be off of it for at least two weeks prior to study treatment.